Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motavizumab and Palivizumab in High-Risk Children
NCT00316264Phase 2Completed
- Sponsor
- MedImmune
- Start
- Apr 2006
- Primary completion
- Feb 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of motavizumab in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Started Apr 2006; status: completed.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00316264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316264.